PTD-DBM: Reference Overview and Reconstitution Notes

PTD-DBM is a man-made research peptide (a short chain of amino acids built in a lab). It belongs to a group of compounds that affect a cell communication system called the Wnt/beta-catenin signaling pathway. It is grouped with healing and tissue-repair research compounds. It is for research only and is not FDA-approved.

PTD-DBM

What it is

PTD-DBM is a man-made research peptide. A peptide is simply a short chain of amino acids (the building blocks that make up proteins). PTD-DBM is built by joining two parts together. The first part is a protein transduction domain (PTD). Think of the PTD like a key that lets the molecule pass through the wall of a cell. The second part is a Dishevelled binding motif (DBM), which connects to a specific protein inside the cell. Together, these two parts act on a cell communication system called the Wnt/beta-catenin signaling pathway (a set of chemical signals that cells use to control growth and repair).

Research context and categorization

Mechanism of Action

PTD-DBM is generally placed in the healing and tissue-repair category. It also overlaps with skin and hair research.

In lab studies, PTD-DBM works by competing with a protein called CXXC5. Both PTD-DBM and CXXC5 try to attach to the same spot on another protein called Dishevelled (Dvl). Dvl is an early step in the Wnt signaling system. Normally, CXXC5 acts like a brake on that system, slowing it down. When PTD-DBM blocks CXXC5 from connecting to Dvl, it removes that brake. This has been studied in cell-based experiments and in animal studies.

Preclinical Studies

In research settings, PTD-DBM is often studied in connection with the Wnt/beta-catenin pathway. It has been looked at for its effects on hair follicles (the tiny pockets in skin where hair grows from) and on wound healing in skin. Some of this work comes from a research group at Yonsei University. These are preclinical studies, meaning they are done in cells or animals, not in people.

Some studies also use PTD-DBM together with valproic acid, a chemical that activates the Wnt pathway, to study how wounds might trigger new hair growth. These uses are investigational only.

As of this writing, there are no completed, peer-reviewed human clinical trials of PTD-DBM. None of the effects described above are confirmed or approved for use in people.

Key point: PTD-DBM is strictly an investigational, research-only peptide with no completed human trials or regulatory approval for clinical use.

Status

• Regulatory status: Research-only. PTD-DBM is not FDA-approved for any use and has no regulatory classification as a bulk drug substance.
• Sport status: PTD-DBM is not listed by name on the WADA Prohibited List (the list of substances banned in organized sport). However, as a synthetic peptide with no regulatory approval, it falls under class S0 (Non-Approved Substances), which is prohibited at all times in sports governed by WADA.

Reconstitution notes (general)

Reconstitution means dissolving a dry powder in liquid to make a working solution. The concentration of that solution (how much peptide is in each milliliter of liquid) is found by dividing the milligrams of peptide in the vial by the milliliters of bacteriostatic water added.

For example, a 5 mg vial mixed with 2 mL of bacteriostatic water gives a solution of 2.5 mg per mL. You can work out any vial-and-volume combination with the calculator at peptide calculator.

Dilution and handling notes (compound-specific)

Solubility and Formulation

PTD-DBM comes as a lyophilized powder. Lyophilized means freeze-dried: the moisture is removed so the compound stays stable on the shelf. It is commonly sold in vials of 1 mg, 2 mg, 5 mg, and 10 mg. The powder must be dissolved in liquid before it can be used in a lab setting.

It is often made as a TFA salt. A salt form pairs the compound with a helper molecule (here, trifluoroacetic acid) that makes the powder dissolve more easily in water. Because of this, the powder usually dissolves in bacteriostatic water without needing anything extra added.

A modest amount of water per vial is the common approach, chosen to reach a workable concentration rather than a very concentrated stock.

Mixing Protocol

PTD-DBM contains a part that does not mix well with water (the hydrophobic transduction domain, similar to how oil resists mixing with water). Because of this, some batches may dissolve slowly or look slightly cloudy if the solution is made too concentrated. Handle reconstitution carefully for best results:

• Add the water gently down the inside wall of the vial rather than directly onto the powder.
• Let the vial sit and swirl slowly rather than shaking it.
• If a batch resists dissolving in plain water, a very small amount of DMSO (a solvent that helps water-resistant compounds dissolve) is sometimes used to pre-wet the powder before diluting into an aqueous buffer.
• Do not force dissolution by vigorous shaking or vortexing, as this can cause foaming or damage the peptide.

Some topical lab preparations in the published literature use a water-plus-DMSO vehicle for this reason. Material that stays visibly undissolved or cloudy is a sign that a solubility limit has been reached, not a dosing cue.

Handling and storage

Store the reconstituted solution in a refrigerator at 2 to 8 °C and keep it away from direct light. Wipe the vial stopper with an alcohol swab before and after each use, and label the vial with the date it was mixed.

A reconstituted peptide solution is generally treated as usable for about 4 weeks when kept refrigerated. Keep the dry powder cold before mixing. Do not freeze the solution once it has been reconstituted.

Discard the vial if the contents turn cloudy, change color, or show visible particles floating in the liquid.

Related reading

• Selank
• Semax
• Sermorelin
• How Reconstitution Works
• How Long Does a Reconstituted Vial Last?

Tools and supplies

• peptide calculator
• Bacteriostatic Water 30 ml
• Gansulin Metal Reusable Pen
• 3 ml Glass Cartridges (10-pack)
• Complete Starter Kit

Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.

Frequently asked questions

What is PTD-DBM and how does it work in preclinical research?

PTD-DBM is a synthetic peptide pairing a protein transduction domain (PTD) with a Dishevelled binding motif (DBM). In cell and animal studies it displaces CXXC5 from the Dvl protein, removing a negative regulator of the Wnt/β-catenin signaling pathway.

Is PTD-DBM prohibited under WADA anti-doping rules?

PTD-DBM is not listed by name on the WADA Prohibited List, but as a non-approved synthetic peptide it falls under class S0 (Non-Approved Substances), which is prohibited at all times in sport governed by WADA rules.

How is PTD-DBM reconstituted for laboratory use?

Divide the peptide mass in the vial (mg) by the volume of bacteriostatic water added (mL) to obtain concentration. Example: 5 mg dissolved in 2 mL bacteriostatic water yields 2.5 mg/mL. Use a peptide calculator for other vial-and-volume combinations.

What the research community gets wrong about PTD-DBM

• Treating lab results as settled. Every reported effect of PTD-DBM comes from cell and animal studies. There are no completed human trials and no regulatory approval. In notes and labels, describe it as preclinical, not proven.
• Calling it a Wnt activator. PTD-DBM does not add signal on its own. It competes with a protein called CXXC5 for the same spot on Dishevelled (Dvl). By taking CXXC5 off that spot, it removes a brake. It is a blocker of a brake, not a booster.
• Reading a cloudy vial as a bad batch. The molecule carries a water-resistant transduction domain, so a hazy or slow-dissolving solution usually means the concentration is too high and a solubility limit was reached. It is a mixing signal, not a quality defect and not a cue to add more powder or liquid beyond your plan.
• Ignoring the salt counterion in the math. The powder is often supplied as a TFA salt, so part of the vial mass is the trifluoroacetic acid helper, not peptide. The net peptide content is lower than the label weight. Note this when you record concentration for a study.
• Shaking or vortexing to speed things up. Hard shaking and vortexing create foam and air/liquid interfaces that can aggregate and damage the peptide. Add water down the vial wall and swirl slowly instead.

From our bench: If you have reconstituted a PTD-DBM vial, we would like your real observation on solubility. Tell us the vial mass (mg), the volume of bacteriostatic water you added (mL), the concentration that gave you, whether a small DMSO pre-wet was used, and how long the solution took to go fully clear or whether any haze remained. Share the numbers you actually measured, and we will add anonymized bench notes to help others plan their mixing.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. Lee SH et al., Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair Neogenesis, J Invest Dermatol 2017 (PMID 28595998)
5. Ryu YC et al., CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD2, Cells 2023 (PMID 36831222)
6. Mehta A et al., Revolutionary Approaches to Hair Regrowth: Follicle Neogenesis, Wnt/beta-Catenin Signaling, and Emerging Therapies, Cells 2025 (PMID 40497955)